Evidence map›Paper›PMID 40692728›Full record

ArticleACG case reports journal2025

Pembrolizumab-Induced Duodenitis Mimicking Celiac Disease.

Yannis Lafazanos, Robin David, Nahren Asado, Miguel Gonzalez, Eli D Ehrenpreis

Abstract readCase Reports
In one paragraph

Article in ACG case reports journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yannis LafazanosInternal Medicine, Advocate Lutheran General Hospital, Park Ridge, IL.
Robin DavidInternal Medicine, Advocate Lutheran General Hospital, Park Ridge, IL.
Nahren AsadoDepartment of Gastroenterology, Advocate Lutheran General Hospital, Park Ridge, IL.
Miguel GonzalezDepartment of Pathology, Advocate Lutheran General Hospital, Park Ridge, IL.
Eli D EhrenpreisDepartment of Medicine, Advocate Lutheran General Hospital, Park Ridge, IL.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pembrolizumab is a programmed cell death-1 (PD-1) inhibitor frequently used as primary immunotherapy in many cancers, including melanoma, lung, renal cell, cervical, urothelial, and gastric cancers. Given its immune-checkpoint inhibition and upregulation of the immune response, pembrolizumab has been associated with many immune system-related adverse effects including stomatitis, conjunctivitis, pneumonitis, myositis, and even type 1 diabetes mellitus. Colitis is the most frequent gastrointestinal adverse reaction, with upper gastrointestinal reactions like esophagitis, gastritis, and duodenitis being rare. In this report, we present a case of pembrolizumab-induced enteropathy that endoscopically and histologically mimicked celiac disease.

Indexed as

immune checkpoint inhibitorsimmune related adverse effectsKeytrudapembrolizumab

Identifiers

PMID40692728
PMCPMC12278897

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.